Paul Dluzniewski is currently a Director in the Center for Observational Research at Amgen. As product area lead for the cardiovascular-metabolic group, his work is focused on therapies used to treat patients at elevated risk of cardiovascular disease. He leads evidence generation efforts by conducting epidemiologic research to inform the benefit-risk profile of Amgen’s therapies and highlight the clinical value of both marketed and pipeline products. Prior to Amgen, he worked as a Senior Research Analyst at Health Net, Inc., a large California-based insurance company, where he analyzed medical provider characteristics to ensure compliance with government regulations.
- PhD, Epidemiology, Johns Hopkins University, Baltimore, MD
- MPH, Epidemiology, Boston University, Boston, MA
- BS, Biology, Massachusetts Institute of Technology, Cambridge, MA
- Cardiovascular Disease
- Epidemiologic methods
- Research Methods
Areas of Interest
Paul’s research is focused on the role of epidemiology in drug development. His current research addresses the development and use of therapies for cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD) and heart failure.
- Levintow SN, Reading SR, Saul BC, Yu Y, Reams D, McGrath LJ, Philip K, Dluzniewski PJ, Brookhart MA. Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines. Clin Epidemiol. 2020 Aug 4;12:835-845.
- Rosenson RS, Hubbard D, Monda KL, Reading SR, Chen L, Dluzniewski PJ, Burkholder GA, Muntner P, Colantonio LD. Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era. J Am Heart Assoc. 2020 Jan 7;9(1):e013744.
- Brookhart MA, Reams D, Dluzniewski PJ, Kshirsagar A, Walsh L, Bradbury BD. Estimating the Effect of Preventable Treatment Discontinuation on Health Outcomes. Epidemiology. 2018 Jan;29(1):134-141.
- Brunelli SM, Sibbel S, Dluzniewski PJ, Cooper K, Bensink ME, Bradbury BD. The association between cinacalcet use and missed in-center hemodialysis treatment rate. Pharmacoepidemiol Drug Saf. 2016 Nov;25(11):1287-1294.
- Dluzniewski PJ, Xu J, Ruczinski I, Isaacs WB, Platz EA. Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):88-93.
- Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD, Xu J, Isaacs WB, Platz EA. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1774-82.